Bank of Jackson Hole Trust Purchases Shares of 8,132 Johnson & Johnson (NYSE:JNJ)

Bank of Jackson Hole Trust acquired a new position in Johnson & Johnson (NYSE:JNJ) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 8,132 shares of the company’s stock, valued at approximately $1,176,000. Johnson & Johnson comprises approximately 0.8% of Bank of Jackson Hole Trust’s investment portfolio, making the stock its 29th largest holding.

Other hedge funds and other institutional investors have also made changes to their positions in the company. International Assets Investment Management LLC lifted its holdings in shares of Johnson & Johnson by 20,130.0% during the third quarter. International Assets Investment Management LLC now owns 3,454,473 shares of the company’s stock valued at $559,832,000 after purchasing an additional 3,437,397 shares during the last quarter. Janus Henderson Group PLC raised its holdings in Johnson & Johnson by 228.1% during the 3rd quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company’s stock worth $549,223,000 after buying an additional 2,356,359 shares during the period. Franklin Resources Inc. boosted its holdings in shares of Johnson & Johnson by 11.4% in the third quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company’s stock worth $2,721,355,000 after buying an additional 1,729,281 shares during the period. Holocene Advisors LP purchased a new position in shares of Johnson & Johnson in the third quarter worth approximately $225,040,000. Finally, FMR LLC raised its holdings in shares of Johnson & Johnson by 7.4% during the third quarter. FMR LLC now owns 18,316,920 shares of the company’s stock valued at $2,968,440,000 after acquiring an additional 1,265,748 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mark A. Weinberger acquired 1,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. 0.16% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Guggenheim raised their price objective on shares of Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a research note on Monday, February 3rd. Stifel Nicolaus decreased their target price on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research report on Thursday, January 23rd. Leerink Partners dropped their price target on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Raymond James decreased their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Trading Up 1.7 %

Johnson & Johnson stock opened at $162.35 on Friday. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The company’s fifty day moving average price is $148.93 and its two-hundred day moving average price is $155.90. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The company has a market capitalization of $390.87 billion, a price-to-earnings ratio of 24.41, a PEG ratio of 2.53 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same quarter in the prior year, the firm posted $2.29 EPS. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. On average, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.06%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.